Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IK-1001 in Acute STEMI Undergoing Primary PCI
NCT01007461Phase 2Withdrawn
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Dec 2009
- Primary completion
- Dec 2009
01
Overview
A Phase 2 trial of sodium sulfide in ST-segment elevation myocardial infarction (STEMI), sponsored by Mallinckrodt Pharmaceuticals. Planned start Dec 2009; status: withdrawn.
02
Drugs
sodium sulfide
03
Conditions
ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT01007461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01007461.